Latest Prostate Cancer News
The risk is highest among patients who switch from anti-androgen to GnRH agonist therapy.
The time to PSA progression in men with relapsing or locally advanced PCa was similar with intermittent and continuous androgen deprivation.
PSA doubling time increased from 28 to 76 months in patients performing exercise training.
Small study shows those undergoing radiation therapy had fewer side effects, less fatigue.
Long-term use of the antiarrhythmic drug, however, may decrease the risk of high-grade prostate cancer.
Researchers investigate sexual dysfunction post RT for localized prostate cancer.
More high-grade cancers detected with MRF-TB vs. systematic biopsy in men undergoing primary biopsy.
Relatively few men with atypical small acinar proliferation are found to have high-grade prostate cancer on repeat biopsy.
But whether that's good or bad isn't yet clear
New analysis shows no significant difference in 10-year progression-free and overall survival among men with high-risk prostate cancer.
Large cost variation over 12 years of follow-up due to equipment, visits.
In small study, olaparib targeted gene mutation in men who had failed other therapy.
Radical prostatectomy was associated with a higher biochemical recurrence-free survival rate compared with radiotherapy.
Men who underwent whole-gland cryoablation had an estimated 5-year biochemical progression-free survival rate of 59.1%.
Problems include longer waits, greater need for more care after surgery, and rehospitalization.
Prostate Cancer Videos
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)